In patients who already have clinical evidence of coronary atherosclerosis there is now clear evidence that several different lipid lowering agents can delay or even reverse the atherosclerotic process reducing the incidence of cardiovascular events and delaying mortality.' 2 However, the relation between atherosclerotic events and the blood cholesterol is poor in practical clinical terms, even though a strong statistical relation exists. More detailed measurements of high and low density lipoproteins and a series of apolipoproteins have strengthened the relation of the lipid profile to clinical events but, with the possible exception of high density lipoprotein cholesterol, have not yet stood the test of time to confirm that they are of real use to the clinician in accurately identifying patients at risk. This suggests that factors other than conventional measures of lipid metabolism may be important in the development of atherosclerosis.
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Acetylation or oxidation of lipids accumulating in the intima is an essential part of the atherosclerotic process, attracting migrating macrophages, enabling them to take up lipids via scavenger receptors, and resulting in the formation of foam cells.34 Plaque growth also involves smooth muscle cell proliferation and collagen deposition. Foam cell death results in the formation of a core of lipid "gruel". Intraplaque haemorrhage and thrombosis are probably the major events leading to rapid plaque expansion: an occurrence that may or may not be clinically apparent. Indeed the incidence of myocardial infarction may be better related to enhanced blood coagulability than to raised blood cholesterol.5 Calcium accumulates usually in areas of cell necrosis and this accumulation may be the final step leading to cell death. However, it is not clear what, if any, pathogenic role calcium has in plaque growth.
Increased understanding of the mechanisms of the development of atherosclerotic plaques suggests several therapeutic targets other than modifying the concentrations of circulating lipids. Antioxidants could reduce the oxidative transformation of lipids and thereby prevent the appearance of foam cells.
Growth factor inhibitors and antimitotic agents could prevent smooth muscle cell proliferation. Antithrombotic agents could prevent thrombosis, though potentially increasing the risk of plaque haemorrhage.
Calcium antagonists could prevent calcium accumulation within the plaque. Other factors such as modulation of sympathetic activity and alterations in membrane charge can be manipulated and could alter atherogenesis. Finally, "crude" mechanical effects such as vasodilatation and increased blood flow either down the vessel or through the nutrient vasa vasorum or reduced heart rate and therefore frequency of mechanical stress should not be discounted.
The clinician may have an academic interest in those processes that lead to atheroma formation but will remain sceptical of their practical relevance until theory is translated into a reduction in vascular events in patients. Animal models are of limited relevance, especially those in which lipid plaques are induced by force feeding high cholesterol diets to herbivorous animals that normally have very little cholesterol in the diet. The histology of the lipid plaques induced in such animals is largely unknown and probably bears scant relation to atheroma.6 Moreover, lipid staining in the aorta is usually reported, because this is expedient, rather than the impact on histologically proven atheroma. Also the relation between aortic and coronary atheroma development may be poor.7 More complex models of atherosclerosis have been developed by selecting strains of animals genetically susceptible to atherosclerosis or by using techniques such as angioplasty to produce endothelial damage. Such models are more expensive and difficult to procure, are studied relatively infrequently, and may still be irrelevant to the human disease.7
Interpretation of studies on human coronary arteries are not without difficulty as plaque only intrudes into the arterial lumen during the later stages of atheroma development and only then is visible on would only be proven to be effective in very long-term studies. Clinicians must be on their guard to distinguish between hypotheses based on experiments in the laboratory and clinically proven facts.
Antioxidants
The rate at which macrophages take up native low density lipoprotein (LDL) is limited by their low expression of the LDL receptor.4 This led to the discovery of alternative scavenger receptors that take up oxidised LDL. Oxidised LDL is chemotactic for circulating macrophages (both directly and by releasing factors from the endothelium), inhibits the motility of tissue macrophages, and is cytotoxic. Uptake of, very low density lipoprotein (VLDL) by macrophages can occur in the absence of modification of lipid particles, giving the appearance of foam cells in the absence of oxidised LDL, but modified LDL is probably the more important pathway in foam cell formation.
Vitamins and related compounds POTENTIAL MECHANISMS OF ACTION
In cell culture high concentrations of vitamin E, vitamin C, a tocopherol, and ,B carotene prevent oxidation of LDL by smooth muscle or endothelial cells. However, the efficiency of these antioxidant effects seem to be subject to great inter-individual variation.8
ANIMAL MODELS
Several studies have examined the effects of vitamins A, C, and E, all of which have antioxidant properties on animal models as mundane as the cholesterol-fed rabbit and as exotic as the Japanese quail.9 These studies showed conflicting evidence of benefit or, in some experiments, harm.'0 This may be due in part to individual variation in vitamin E dependent and independent oxidative resistance. Vitamin E reduced serum cholesterol in some, but not all, studies." 12 Adding these controversies to those of the precise significance of aortic lipid deposition in relation to atherosclerosis should induce a healthy degree of scepticism.
Dihydropyridine calcium antagonists HUMAN STUDIES
In contrast to the small numbers of animals treated experimentally there are several large well controlled studies of dihydropyridine calcium antagonists in patients with minor coronary artery disease, after myocardial infarction both short and long term, and in unstable angina and in heart failure.4>50 These studies have consistently failed to show a reduction in myocardial infarction or mortality, rather the reverse.
Two well controlled studies did not show any significant overall effect of the dihydropyridine calcium antagonists nifedipine and nicardipine on the progression of coronary artery disease.4647 The INTACT study suggested a reduction in the appearance of new lesions by about 28% that just achieved statistical significance. 46 The study by Waters et al suggested that lesions of < 20% (lesions < 20% were considered not to be definite stenoses in the INTACT study) were half as likely to progress if the patient was treated with nicardipine. 47 The fact that the findings were made independently argues for a real effect. However, these findings may have occurred by chance owing to the numerous comparisons made within the studies, and the possibility of artefact should be considered. A coronary stenosis may appear less severe in a dilated vessel if the atheromatous plaque is eccentric and the segment can relax. The INTACT study had an all cause mortality of 12 on nifedipine but only 2 on placebo (p < 0 05), which is worrying. Although the mortality in the study by Waters et al was not increased by nicardipine there were 17 infarcts in the active group versus nine in the control-again a trend in the wrong direction. There is only one major outcome trial of diltiazem in humans.5" This study in patients after myocardial infarction showed no overall effect on mortality. Those patients with heart failure did worse with diltiazem treatment,52 and exclusion of this group from analysis suggested that outcome may have been improved in the remaining participants. Two large postinfarction studies with verapamil have been reported.53 54 These showed a trend to reduced mortality, that became significant if patients with heart failure were excluded from analysis. All three studies indicated a reduction in recurrent myocardial infarction with these agents.
A study examining the effects of verapamil on the progress of minor coronary disease is being conducted by Kober et 63 Consideration of the similar benefits of verapamil and the 16 blockers after myocardial infarction, at least in the absence of heart failure, suggest that heart rate reduction might be the cause of the reduction in cardiovascular events. Limitation of increases in heart rate is obviously a powerful way of reducing myocardial ischaemia and may reduce atherogenesis. Atheromatous lesions are most likely to develop at the bifurcation of vessels at points where the vessel wall is exposed to high shear stress to the intima and possibly to greater mechanical stress of the vessel wall. Reductions in myocardial oxygen demand and therefore blood flow may reduce shear stresses. Reduction in the frequency of cardiac contraction may reduce the mechanical stress on the coronary vessel walls. 
Nitrates
The function of the endothelium adjacent to an atherosclerotic plaque is abnormal. It does not release endothelium-derived relaxing factor and this, in turn, has been considered by some to contribute to the development of atherosclerosis.
Isosorbide dinitrate can inhibit platelet aggregation. However group.bmj.com on June 19, 2017 -Published by http://heart.bmj.com/ Downloaded from number of participants) conducted in the United States implied that aspirin could reduce the risk of myocardial infarction by about 50%.88 However, aspirin had no effect on overall cardiovascular mortality. This apparent discrepancy was largely due to an excess of sudden deaths in the aspirin treated group, a mode of death that was included with myocardial infarction in the British study. In the United States study the ratio of non-fatal to fatal myocardial infarction was about 10:1 whereas in the British study it was 1:1. These disparities are unexplained.
A follow up of the United States study on primary prevention has indicated that the effect of aspirin in reducing myocardial infarction begins soon after start of treatment and the magnitude of the effect does not increase with time, implying no reduction in the development of atheroma89 but rather an effect on thrombotic occlusion. However, studies on peripheral vascular disease have suggested that aspirin may retard the progress of atheroma.90
OTHER ANTI-PLATELET AGENTS
In general the addition of dipyridamole to aspirin did not further reduce vascular complications compared with aspirin alone in clinical studies of cerebral or peripheral vascular disease.89 Ticlopidine showed promise in several recent studies of patients with peripheral vascular disease. It reduced total and cardiac mortality and retarded the angiographic progression of peripheral vascular disease.9' 92 Inhibition of thrombin-mediated platelet aggregation may prove a more powerful method of retarding atheroma formation than aspirin. 105 Neri Serneri et al compared the effects of long-term (23 months) low dose (12 500 IU once daily) heparin and placebo in 728 patients after myocardial infarction.'06 Heparin achieved a reduction in total mortality of borderline statistical significance (34% reduction by intention to treat and 48% on an on-treatment analysis) and reinfarction was reduced by 63%. Inhalation of heparin by nebuliser seems to be an effective, feasible and more acceptable alternative to subcutaneous injection and may need to be administered as infrequently as once every two weeks.102 107 
Warfarin POTENTIAL MECHANISMS OF ACTION
The incidence of coronary events is as, or more, closely related to plasma concentrations of factor VII activity and fibrinogen than to cholesterol. Warfarin considerably reduces factor VII activity. Reduction in nonocclusive thrombotic events could retard the rapid progress of atheroma. Reduction of occlusive events may lead to reductions in the incidence of sudden death and myocardial infarction.
ANIMAL STUDIES
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